Silence Therapeutics (SLN) News Today $5.00 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$5.00 +0.00 (+0.10%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period AC Immune (NASDAQ:ACIU) vs. Silence Therapeutics (NASDAQ:SLN) Critical ContrastFebruary 17 at 3:15 AM | americanbankingnews.comShort Interest in Silence Therapeutics plc (NASDAQ:SLN) Rises By 15.0%Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,300,000 shares, an increase of 15.0% from the January 15th total of 1,130,000 shares. Based on an average daily volume of 565,200 shares, the days-to-cover ratio is presently 2.3 days.February 16, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Research Coverage Started at The Goldman Sachs GroupFebruary 14, 2025 | americanbankingnews.comGoldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell RecommendationFebruary 11, 2025 | msn.comSilence Therapeutics hit with new Sell at Goldman Sachs on resource constraintsFebruary 11, 2025 | seekingalpha.comSilence Therapeutics initiated with a Sell at Goldman SachsFebruary 11, 2025 | markets.businessinsider.comGoldman starts Silence Therapeutics at Sell on ‘undifferentiated’ dataFebruary 11, 2025 | markets.businessinsider.comGoldman Sachs cuts Silence Therapeutics stock rating to SellFebruary 11, 2025 | msn.comThe Goldman Sachs Group Begins Coverage on Silence Therapeutics (NASDAQ:SLN)The Goldman Sachs Group initiated coverage on Silence Therapeutics in a report on Tuesday. They issued a "sell" rating and a $6.00 target price on the stock.February 11, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of SLN FY2024 EarningsSilence Therapeutics plc (NASDAQ:SLN - Free Report) - HC Wainwright dropped their FY2024 earnings per share estimates for shares of Silence Therapeutics in a note issued to investors on Wednesday, January 29th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earningsFebruary 3, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Buy" from BrokeragesSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price amongFebruary 2, 2025 | marketbeat.comAnalysts Issue Forecasts for SLN FY2029 EarningsSilence Therapeutics plc (NASDAQ:SLN - Free Report) - HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Silence Therapeutics in a report released on Wednesday, January 29th. HC Wainwright analyst P. Trucchio forecasts that the company will earn $0.66 per share for the year.January 31, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Wednesday.January 29, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Recommendation of "Buy" from AnalystsShares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have been given a consensus rating of "Buy" by the six brokerages that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages thaJanuary 8, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Down 9.3% - Here's What HappenedSilence Therapeutics (NASDAQ:SLN) Stock Price Down 9.3% - What's Next?January 8, 2025 | marketbeat.comSilence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right NowDecember 18, 2024 | insidermonkey.comSilence Therapeutics plc (NASDAQ:SLN) Receives Consensus Rating of "Buy" from AnalystsShares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objeDecember 14, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest UpdateSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 702,300 shares, an increase of 84.1% from the November 15th total of 381,500 shares. Based on an average daily volume of 403,300 shares, the days-to-cover ratio is presently 1.7 days.December 12, 2024 | marketbeat.comSilence Therapeutics announces additional results from SANRECO studyDecember 10, 2024 | markets.businessinsider.comChardan Capital Reaffirms Buy Rating for Silence Therapeutics (NASDAQ:SLN)Chardan Capital restated a "buy" rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday.December 10, 2024 | marketbeat.comSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | businesswire.comPoint72 Asset Management L.P. Buys 321,300 Shares of Silence Therapeutics plc (NASDAQ:SLN)Point72 Asset Management L.P. lifted its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 219.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 467,800 shares of tDecember 8, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Purchased by Janus Henderson Group PLCJanus Henderson Group PLC raised its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 32.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,087,228 shares of the company's stock after purchasing an addDecember 8, 2024 | marketbeat.comRedmile Group LLC Has $34.53 Million Stake in Silence Therapeutics plc (NASDAQ:SLN)Redmile Group LLC lowered its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 5.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,899,317 shares of the company's stock after selling 114,979December 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Boosts Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)Parkman Healthcare Partners LLC raised its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 71.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 497,870 shares of the company's stoDecember 4, 2024 | marketbeat.com640,000 Shares in Silence Therapeutics plc (NASDAQ:SLN) Bought by Eventide Asset Management LLCEventide Asset Management LLC bought a new position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 640,000 shares of the company's stock, valued at approximately $11,635,00November 29, 2024 | marketbeat.comSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | finance.yahoo.comSilence Therapeutics weakness after AHA updates ‘overdone,’ says BMO CapitalNovember 20, 2024 | markets.businessinsider.comSilence Therapeutics' Zerlasiran Has Competitive Concerns: AnalystNovember 19, 2024 | benzinga.comSilence Therapeutics plc (NASDAQ:SLN) Given Consensus Recommendation of "Buy" by BrokeragesShares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month tNovember 19, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives "Outperform" Rating from William BlairWilliam Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comSilence Therapeutics presents late-breaking Phase 2 zerlasiran data at AHANovember 19, 2024 | markets.businessinsider.comSilence Therapeutics Showcases Promising Phase 2 ResultsNovember 19, 2024 | markets.businessinsider.comSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingNovember 18, 2024 | businesswire.comSilence Therapeutics (NASDAQ:SLN) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comSilence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | finanznachrichten.deSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNovember 14, 2024 | finance.yahoo.comIs Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?October 31, 2024 | uk.finance.yahoo.comSilence Therapeutics (SLN) Gets a Buy from Morgan StanleyOctober 22, 2024 | markets.businessinsider.comCubist Systematic Strategies LLC Has $179,000 Position in Silence Therapeutics plc (NASDAQ:SLN)Cubist Systematic Strategies LLC lowered its holdings in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 74.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,438 shares of the company's stock after sellingOctober 15, 2024 | marketbeat.comRenaissance Technologies LLC Sells 64,800 Shares of Silence Therapeutics plc (NASDAQ:SLN)Renaissance Technologies LLC cut its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 62.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,100 shares of the company's stock after selliOctober 9, 2024 | marketbeat.comMorgan Stanley Reaffirms Overweight Rating for Silence Therapeutics (NASDAQ:SLN)Morgan Stanley reiterated an "overweight" rating and issued a $49.00 target price on shares of Silence Therapeutics in a report on Tuesday.October 8, 2024 | marketbeat.comMillennium Management LLC Buys 373,523 Shares of Silence Therapeutics plc (NASDAQ:SLN)Millennium Management LLC raised its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 91.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 782,941 shares of the company's sOctober 7, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Stock Price Down 3.7% - Here's What HappenedSilence Therapeutics (NASDAQ:SLN) Stock Price Down 3.7% - What's Next?October 4, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading 3.6% Higher Silence Therapeutics (NASDAQ:SLN) Shares Up 3.6%October 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Raises Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)Point72 Asset Management L.P. lifted its holdings in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 1,686.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 146,500 shares of the company's stock after purchasing aOctober 3, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sees Large Volume IncreaseSilence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeSeptember 25, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) is M28 Capital Management LP's 6th Largest PositionM28 Capital Management LP lowered its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 38.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 185,100 shares of the company's stock after selliSeptember 21, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeSilence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeSeptember 17, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Sees Significant Drop in Short InterestSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 254,600 shares, a drop of 27.4% from the August 15th total of 350,500 shares. Based on an average daily trading volume, of 222,600 shares, the days-to-cover ratio is presently 1.1 days.September 14, 2024 | marketbeat.com Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address SLN Media Mentions By Week SLN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLN News Sentiment▼0.600.57▲Average Medical News Sentiment SLN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLN Articles This Week▼32▲SLN Articles Average Week Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SEPN News PGEN News STOK News CGEM News AUTL News VALN News XERS News TECX News MGTX News MLYS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLN) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
